Active Psoriatic ArthritisPhase 2NCT02980692
Efficacy and Safety Study of SUNPG1623
A Phase 2 study testing SUNPG1623 I, SUNPG1623 II and SUNPG1623 III in people with Active Psoriatic Arthritis, run by Sun Pharmaceutical Industries Limited at 1 site in United States.
Trial summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623 Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Active Psoriatic Arthritis
- What is being tested?
- SUNPG1623 I, SUNPG1623 II and SUNPG1623 III
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 391 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Apr 2017to 24 Sep 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject has provided written informed consent
- Subject is ≥ 18 years of age at time of Screening
- Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
- Subject has a negative evaluation for TB within 4 weeks before initiating IMP
- Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis [CASPAR] criteria) with symptoms present for at least 6 months.
- Subject has ≥ 3 tender and ≥ 3 swollen joints at Screening and Baseline.
Who cannot join
- Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition
- Subject has an active infection or history of infections
- Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease
- Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
- Conditions
- Active Psoriatic Arthritis
- Being tested
- SUNPG1623 I, SUNPG1623 II, SUNPG1623 III, SUNPG1623 IV, PLACEBO
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SUNPG1623 IDrug
injection
SUNPG1623 IIDrug
injection
SUNPG1623 IIIDrug
injection
SUNPG1623 IVDrug
injection
PLACEBODrug
injection
| Study group | Role | What they receive |
|---|---|---|
| SUNPG1623 dose I | Experimental | low range dose Receives: Drug: SUNPG1623 I |
| SUNPG1623 dose II | Experimental | mid range dose Receives: Drug: SUNPG1623 II; Drug: PLACEBO |
| SUNPG1623 dose III | Experimental | mid range dose Receives: Drug: SUNPG1623 III; Drug: PLACEBO |
| SUNPG1623 dose IV | Experimental | mid range dose to high dose Receives: Drug: SUNPG1623 IV; Drug: PLACEBO |
| Placebo | Placebo comparator | mid range dose to high dose Receives: Drug: PLACEBO |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.
For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Measured: week 24
Secondary outcomes (26)
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.
For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Measured: week 52
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
The American College of Rheumatology50 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.
For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
The American College of Rheumatology70 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein.
For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52
Change From Baseline in Tender Joint Counts
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Tender Joint Counts
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Measured: Week 52
Change From Baseline in Swollen Joint Counts
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Swollen Joint Counts
Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.
Measured: Week 52
Physician Global Assessment of Disease Activity Visual Analog Scale
100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale
100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)
Measured: Week 52
Patient's Global Assessment of Disease Activity
100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)
Measured: week 1, week 4, week 8, week 12, week 16, week 20 and week 24
Change From Baseline in Patient's Global Assessment of Disease Activity
100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)
Measured: Week 52
Patient's Pain Assessment
100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Patient's Pain Assessment
100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).
Measured: Week 52
Health Assessment Questionnaire- Disability Index
eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).
The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Health Assessment Questionnaire- Disability Index
eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do).
The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability
Measured: Week 52
Acute Phase C - Reactive Protein
C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.
CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Acute Phase C - Reactive Protein
C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood.
CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation.
Change from Baseline in C-Reactive Protein.
Measured: Week 52
Erythrocyte Sedimentation Rate
An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Erythrocyte Sedimentation Rate
An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.
Measured: Week 52
The Proportion of Subjects Who Require Adjustment of Background Therapy
Measured: Week 16
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
The Disease Activity Score 28-item C-Reactive Protein: assessed across 28 joints including the shoulder, elbow, wrist, MCP (1 through 5), PIP (1 through 5) and knee, with all 14 joints assessed for each side of the body. It is a composite score derived from examination of the 28 joints for swelling and tenderness, global assessment of pain and overall status using a VAS and a blood marker of inflammation (hsCRP).
DAS28-CRP(4) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 TJC- tender joint count, SJC- swollen joint count, CRP- C reactive protein, GH - patient global health
Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52
Minimal Disease Activity
A psoriatic arthritis patient is defined as having a Minimal Disease Activity (MDA) response (Yes/No) when the patient meets at least 5 of the 7 following criteria:
- tender joint count ≤1;
- swollen joint count ≤1;
- PASI score ≤1 or BSA ≤3%;
- patient Arthritis Pain (VAS) ≤15 mm;
- patient's global arthritis assessment (VAS) ≤20 mm;
- HAQ-DI score ≤0.5;
- tender entheseal points (using LEI) ≤1.
Measured: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52
Change From Baseline in Leeds Dactylitis Index (LDI)
tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)
Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score
Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45
The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.
Lower Leeds Dactylitis Index score represent better outcome.
Measured: week 4, week 12, and week 24
Change From Baseline in Leeds Dactylitis Index (LDI)
tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw)
Total score= {[Circumference involved digit/ Circumference contralateral Digit (or Tables)] - 1x 100}x Tenderness score
Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45
The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index.
Lower Leeds Dactylitis Index score represent better outcome.
Measured: Week 52
Change From Baseline in Leeds Enthesitis Index (LEI)
The LEI examines tenderness at 6 sites:
2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.
Lower the score better is the outcome
Measured: week 4, week 12 and week 24
Change From Baseline in Leeds Enthesitis Index (LEI)
The LEI examines tenderness at 6 sites:
2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6.
Lower the score better is the outcome
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2016 (estimated)
- Study start19 Apr 2017
- Primary completion1 Mar 2019
- Study completion24 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Active Psoriatic ArthritisStudies of the same condition, open and under way.
- More trials run by Sun Pharmaceutical Industries LimitedThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 391 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02980692
- Sponsor's protocol ID
- CLR_16_23
- Status last verified
- Aug 2022
- First submitted
- 30 Nov 2016
- Last updated
- 27 Jan 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.
PubMed 33985942
Study at a glance
From the registry record, last updated by the sponsor on 27 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis
- ClinicalTrials.gov ID
- NCT02980692
- Acronym / sponsor ID
- CLR_16_23
- Conditions
- Active Psoriatic Arthritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 391 participants (actual)
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry (pharma, biotech, devices)
- Study start
- 19 Apr 2017 (actual)
- Primary completion
- 1 Mar 2019 (actual)
- Study completion
- 24 Sep 2019 (actual)
- First posted
- 2 Dec 2016 (estimated)
- Results
- Posted 19 May 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| SUNPG1623 dose I | Experimental | Drug: SUNPG1623 Ilow range dose |
| SUNPG1623 dose II | Experimental | Drug: SUNPG1623 II, Drug: PLACEBOmid range dose |
| SUNPG1623 dose III | Experimental | Drug: SUNPG1623 III, Drug: PLACEBOmid range dose |
| SUNPG1623 dose IV | Experimental | Drug: SUNPG1623 IV, Drug: PLACEBOmid range dose to high dose |
| Placebo | Placebo comparator | Drug: PLACEBOmid range dose to high dose |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subject has provided written informed consent
- Subject is ≥ 18 years of age at time of Screening
- Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP
- Subject has a negative evaluation for TB within 4 weeks before initiating IMP
- Subject has a diagnosis of PsA (by the Classification of Psoriatic Arthritis [CASPAR] criteria) with symptoms present for at least 6 months.
Key exclusion criteria (4 listed)
- Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition
- Subject has an active infection or history of infections
- Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease
- Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SUNPG1623 Iinjection | Drug | SUNPG1623 dose I |
| SUNPG1623 IIinjection | Drug | SUNPG1623 dose II |
| SUNPG1623 IIIinjection | Drug | SUNPG1623 dose III |
| SUNPG1623 IVinjection | Drug | SUNPG1623 dose IV |
| PLACEBOinjection | Drug | Placebo, SUNPG1623 dose II, SUNPG1623 dose III, SUNPG1623 dose IV |
Primary outcome
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
Time frame: week 24
The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.
26 secondary outcomes
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
Time frame: week 52
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52
Change From Baseline in Tender Joint Counts
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Tender Joint Counts
Time frame: Week 52
Change From Baseline in Swollen Joint Counts
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Swollen Joint Counts
Time frame: Week 52
Physician Global Assessment of Disease Activity Visual Analog Scale
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale
Time frame: Week 52
Patient's Global Assessment of Disease Activity
Time frame: week 1, week 4, week 8, week 12, week 16, week 20 and week 24
Change From Baseline in Patient's Global Assessment of Disease Activity
Time frame: Week 52
Patient's Pain Assessment
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Patient's Pain Assessment
Time frame: Week 52
Health Assessment Questionnaire- Disability Index
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Health Assessment Questionnaire- Disability Index
Time frame: Week 52
Acute Phase C - Reactive Protein
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Acute Phase C - Reactive Protein
Time frame: Week 52
Erythrocyte Sedimentation Rate
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, and week 24
Change From Baseline in Erythrocyte Sedimentation Rate
Time frame: Week 52
The Proportion of Subjects Who Require Adjustment of Background Therapy
Time frame: Week 16
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52
Minimal Disease Activity
Time frame: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52
Change From Baseline in Leeds Dactylitis Index (LDI)
Time frame: week 4, week 12, and week 24
Change From Baseline in Leeds Dactylitis Index (LDI)
Time frame: Week 52
Change From Baseline in Leeds Enthesitis Index (LEI)
Time frame: week 4, week 12 and week 24
Change From Baseline in Leeds Enthesitis Index (LEI)
Time frame: Week 52
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jan 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33985942Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, Chou RC, Mendelsohn AM, Rozzo SJ, Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-1157. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.
- Individual participant dataSharing planned: Undecided
Related trials for Active Psoriatic Arthritis
Active, not recruitingPhase 3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Psoriatic Arthritis (PsA)
Not yet recruitingPhase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Psoriatic Arthritis
RecruitingPhase 3
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
RecruitingPhase 3
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Active Juvenile Psoriatic Arthritis
Active, not recruitingPhase 3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SUNPG1623 I, SUNPG1623 II and SUNPG1623 III in people with Active Psoriatic Arthritis, run by Sun Pharmaceutical Industries Limited at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate (time frame: week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02980692, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2023.